Loading…
Chinese maker of chromatography and filtration consumables used to purify biopharmaceutical drugs.
Chinese maker of chromatography and filtration consumables used to purify biopharmaceutical drugs.
Sells the resin beads and filled columns that separate a drug from impurities, and these are used up batch after batch. Once a customer's purification step is approved, replacement orders repeat. It competes against imported media from large foreign suppliers as Chinese drugmakers look for local sources.
In one line: A Chinese Cytiva/Repligen for bioprocess purification consumables.
Moat: narrow (switching costs, process know-how). Validated purification consumables are costly for a drugmaker to swap mid-process.
Headquarters: Suzhou, Jiangsu, China · Employees: 417
Size Suzhou Sepax Technologies (688758.SS) is a China Health Care company (Medical Specialties) with a market value of $1.45B, the 1679th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥23.19 on 6 Nov 2026.
Performance Over six months the shares gained 19.1%, against -7.9% for the median peer and -16.4% for the China market (cap-weighted) — 3rd highest of 20 in its peer set.
Growth Revenue grew 27.6% over the last twelve months (peer median +7.3%); the operating margin is 39.5% (peer median 15.3%).
Valuation It trades at 50.8× forward earnings against a peer median of 21.8× (2nd most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 25% a year for seven years (Req g). Recent delivered growth is +24%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 12.6 points above its cost of capital (8.0% WACC).
Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥525M | CN¥400M | CN¥314M | CN¥244M | CN¥212M |
| Revenue growth | — | +28% | +28% | +15% | — |
| Gross profit | CN¥390M | CN¥270M | CN¥210M | CN¥162M | CN¥153M |
| EBITDA | n/a | CN¥144M | CN¥102M | CN¥64.8M | CN¥56.1M |
| Net income | CN¥198M | CN¥127M | CN¥85.2M | CN¥52.5M | CN¥47.1M |
| Free cash flow | CN¥109M | CN¥116M | CN¥55.6M | CN¥27.0M | -CN¥13.6M |
| Capital expenditure | CN¥78.8M | CN¥14.0M | CN¥13.5M | CN¥19.1M | CN¥48.7M |
| Total debt | CN¥171M | CN¥55.6M | CN¥43.9M | CN¥49.0M | CN¥51.5M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Suzhou Sepax Technologies 688758.SS | $1.45B | +19% | +28% | 40% | 50.8× | 24.7% |
| Danaher DHR | $162B | +35% | +6% | 21% | 25.3× | 20.5% |
| Repligen RGEN | $11.1B | +41% | +14% | 9% | 71.3× | 56.4% |
| Sartorius SRT.DE | $20.0B | +34% | +4% | 18% | 42.6× | 24.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688758.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -22.1% | +4.7% | 2nd lowest of 21 |
| 6-month return | +19.1% | -7.9% | 3rd highest of 20 |
| Distance from 52-week high | -33.3% | -22.8% | 8th lowest of 21 |
| Revenue growth (TTM) | +27.6% | +7.3% | 4th highest of 20 |
| Operating margin | 39.5% | 15.3% | 2nd highest of 20 |
| Forward P/E | 50.8× | 21.8× | 2nd most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 24.7% | 10.8% | 2nd most demanding of 13 |
| Growth delivered (Del g) | +23.6% | +17.4% | 3rd highest of 13 |
| Hurdle (Req g minus delivered) | +1.1 pp | -5.2 pp | 5th most demanding of 13 |
| ROIC minus cost of capital | +12.6 pp | +0.9 pp | 2nd highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Suzhou Sepax Technologies 688758.SS | China | $1.45B | +19% | +28% | 40% | 50.8× | 24.7% | +23.6% |
| El.En ELN.MI | Italy | $1.44B | +11% | +3% | 15% | 21.8× | 9.8% | +7.7% |
| Beijing Balance Medical Technology 688198.SS | China | $1.47B | -26% | +10% | 28% | 46.6× | 22.6% | +27.6% |
| Ovctek China 300595.SZ | China | $1.42B | -26% | 0% | 28% | 20.8× | 9.9% | +16.5% |
| Nakanishi 7716.T | Japan | $1.42B | +8% | +15% | 19% | 16.3× | 2.2% | +19.7% |
| Sonoscape Medical 300633.SZ | China | $1.42B | -8% | +18% | 4% | 36.8× | n/a | n/a |
| CONMED CNMD | United States | $1.53B | +40% | +2% | 2% | 11.1× | 32.4% | +9.8% |
| Sansure Biotech 688289.SS | China | $1.36B | -8% | -1% | 1% | 39.0× | n/a | n/a |
| NovoCure NVCR | United States | $1.55B | -26% | +13% | -17% | n/a | n/a | n/a |
| NIPRO 8086.T | Japan | $1.55B | -9% | +3% | 6% | 14.9× | n/a | n/a |
| Enovis ENOV | United States | $1.57B | +2% | +5% | 3% | 7.7× | 22.3% | -6.0% |
| Sinocare 300298.SZ | China | $1.58B | +15% | +7% | 6% | 23.6× | 10.8% | +18.3% |
| Shanghai MicroPort Endovascular MedTech 688016.SS | China | $1.59B | -14% | +16% | 44% | 17.2× | 3.1% | +23.4% |
| Shenzhen Edge Medical 2675.HK | Hong Kong | $1.31B | -51% | +132% | 2% | 130.1× | n/a | n/a |
| Nihon Kohden 6849.T | Japan | $1.63B | +8% | +1% | 7% | 17.6× | -2.1% | +3.3% |
| Vitrolife VITR.ST | Sweden | $1.63B | +14% | -2% | 19% | 27.6× | 22.0% | +22.5% |
| Molbio Diagnostics MOLBIO.NS | India | $1.63B | n/a | +35% | 17% | n/a | n/a | n/a |
| Alpha Tau Medical DRTS | United States | $1.27B | +61% | n/a | n/a | n/a | n/a | n/a |
| Eyebright Medical Technology (Beijing) 688050.SS | China | $1.27B | -15% | +21% | 16% | 25.2× | 10.8% | +40.3% |
| STAAR Surgical STAA | United States | $1.26B | -6% | +51% | 18% | 45.8× | n/a | n/a |
| Rigaku 268A.T | Japan | $1.66B | -57% | +5% | 15% | 20.4× | 18.8% | +14.5% |